The plus signs in online sermorelin

The GHRH + GHRP-6 experiment

In 1990, Bowers and colleagues gave healthy volunteers GHRH and GHRP-6 separately and together. Together, the peptides produced a growth-hormone response several-fold greater than either alone. That is a satisfying experimental result: two different inputs meeting at the same hormone-producing cell, with an unexpectedly large output.

The comparison has a spareness I admire. Each ingredient gets its turn; then the pair gets its turn. The outcome was growth hormone in blood. Adult sleep, recovery, fat loss and the effects of prolonged treatment remain separate questions.

The pairing in that paper was GHRH with GHRP-6. Online discussion often replaces the second name with ipamorelin. I want the original names audible, because changing an ingredient changes the experiment being discussed.

Sermorelin and ipamorelin

Sermorelin copies the first 29 amino acids of growth hormone-releasing hormone, the signal that prompts the pituitary to release growth hormone. A secretagogue is simply a substance that prompts secretion. Ipamorelin acts through the ghrelin receptor, a different input to the same system. The two receptor pathways help explain the interest in combinations.

The bundled benefits ask too much of that finding, in my judgment. A larger hormone response establishes something real and specific. Put everyday function and adverse effects beside the hormone measurements, and my interest would increase.

The combination research is the starting point for a closer look at the two inputs.

Other additions to the claim

There are other plus signs, even when the symbol disappears. A childhood growth result gets added to an adult wellness claim. A tesamorelin cognition result gets added to sermorelin. A former approval gets added to a present compounded preparation. Each addition deserves its own explanation.

Sermorelin has a documented pediatric treatment history. The controlled cognition trial used tesamorelin, a related GHRH analog. And the FDA withdrawal determination preserves the former product’s history; each current compounded medicine has no FDA approval. Those distinctions give the subject texture; flattening them into one success story loses the most interesting parts.

Choose a question

The research page follows the original combination and the pituitary machinery. Effects and safety considers the goals people describe, the adverse reports and the clinical findings. The study quantities page holds the historical regimens, with their populations attached.

For the approval history, compounding and sport rules, there are questions about status. The reading list collects the sources. Carefully bounded results earn my confidence; benefit lists that lengthen with every retelling spend it.